Thumbnail Image
Publication

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

Dutton, S
; 
Ferry, D
; 
Blazeby, J
; 
Abbas, H
; 
Dahle-Smith, A
; 
Mansoor, Was
; 
Thompson, J
; 
Harrison, M
; 
Chatterjee, Anirban
; 
Falk, S
... show 10 more
Citations
Altmetric:
Abstract
Evidence is scarce for the effectiveness of therapies for oesophageal cancer progressing after chemotherapy, and no randomised trials have been reported. We aimed to compare gefitinib with placebo in previously treated advanced oesophageal cancer.
Authors
Dutton, S
Ferry, D
Blazeby, J
Abbas, H
Dahle-Smith, A
Mansoor, Was
Thompson, J
Harrison, M
Chatterjee, Anirban
Falk, S
Garcia-Alonso, A
Fyfe, David W
Hubner, Richard A
Gamble, T
Peachey, L
Davoudianfar, M
Pearson, S
Julier, P
Jankowski, J
Kerr, R
Petty, R
Affiliation
Oxford Clinical Trials Research Unit and Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK.
Description
Date
2014-07
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. 2014, 15 (8):894-904 Lancet Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/322584
Embedded videos